Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacyBriana R. Halle, Veronica Rotemberg, Mario E. Lacouture et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 64
Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse eventsSean Singer, Nicole R. LeBoeuf, Sally Tan et al.|Journal of the American Academy of Dermatology|2019Cited by 44
Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibitionAnna K. Dewan, Nicole R. LeBoeuf, Sameer Gupta et al.|JAAD Case Reports|2019Cited by 10
Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade Using Tissue Cyclic Immunofluorescence: A Pilot StudyZoltan Maliga, Nicole R. LeBoeuf, Daniel Y. Kim et al.|Journal of Investigative Dermatology|2024Cited by 2
Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic ImmunofluorescenceZoltan Maliga, Nicole R. LeBoeuf, Daniel Y. Kim et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 0